Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

116.58 -8.13 (-6.52%)
Streaming Delayed Price Updated: 3:34 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,578,423
Open 121.40
Bid (Size) 116.50 (1)
Ask (Size) 116.72 (4)
Prev. Close 124.71
Today's Range 116.00 - 122.99
52wk Range 76.53 - 131.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
From BioNTech SE
Via GlobeNewswire

Performance

YTD
+3.77%
+3.77%
1 Month
+29.63%
+29.63%
3 Month
+35.13%
+35.13%
6 Month
+23.86%
+23.86%
1 Year
+6.91%
+6.91%

More News

Read More
Here's Why Everyone's Talking About Summit Therapeutics
Via The Motley Fool
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Via Benzinga
Exposures COVID-19
Forecasting The Future: 8 Analyst Projections For BioNTech
Via Benzinga
Market Whales and Their Recent Bets on BNTX Options
Via Benzinga
Unveiling 12 Analyst Insights On BioNTech
Via Benzinga
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Via Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Via Benzinga
Exposures COVID-19
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Via Benzinga
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
From BioNTech SE
Via GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Via FinancialNewsMedia
Exposures COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
Via Benzinga
Exposures COVID-19
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
Via Talk Markets
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Via Benzinga
Exposures COVID-19
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
Via Benzinga
Exposures COVID-19
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
Via Benzinga
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.